The table below shows BridgeBio Pharma, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$502.08M
$221.90M
$9.30M
$77.65M
$69.72M
$8.25M
Cost of revenue
$20.96M
$3.88M
$2.45M
$3.43M
$3.11M
-
Gross profit
-
-
-
-
-
-
R&D
$451.95M
$506.46M
$455.71M
$399.46M
$451.02M
$337.05M
SG&A
BBIO annual revenue (10-K history)
BridgeBio Pharma, Inc. reported annual revenue of $502.08M for fiscal year 2025. That is up 126.3% from $221.90M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $40.56M (FY 2019) to $502.08M. Figures come from the company's audited annual reports as filed with the SEC.
